RXRX vs SHPH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RXRX and SHPH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RXRX and SHPH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026) and comes mostly from partnerships rather than drug sales.

Full RXRX guide

Shuttle Pharmaceuticals Holdings, Inc. began as a clinical-stage biopharmaceutical company spun out of research at Georgetown University, focused on radiation therapy and drugs that make tumors more sensitive to radiation. Its lead candidate, ropidoxuridine (IPdR), was an oral radiation sensitizer being studied in a Phase 2 trial for newly diagnosed glioblastoma, and it carried FDA Orphan Drug Designation. For most of its public life the company generated no product revenue and funded operations through equity raises, the typical profile of an early-stage biotech whose value depended on clinical trial outcomes.

Full SHPH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• RXRX drivers: An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book.
• SHPH drivers: Pivot to an AI drug-discovery platform; Exposure to the AI-in-healthcare theme.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output. For SHPH, the risks here are severe and should not be understated.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RXRX if you believe its drivers more; SHPH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RXRX and SHPH guides.

RXRX. Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. Q1 2026 showed narrower losses driven by sizable cuts to R&D and overhead, which extended the stated runway into early 2028, but revenue came in well below analyst expectations. For a story like this, valuation is ultimately a bet on future platform output and partnership milestones rather than on current financial performance.

SHPH. These characterizations are directional and tied to the asOf date, not precise live figures. Micro-cap financials like Shuttle's change quickly, especially through frequent financings that alter cash balances and share counts, and the recent pivot means historical numbers may not reflect the current business. Going-concern language is a serious signal that the company needs continued outside capital to operate. Always verify the latest cash position, share count, revenue, losses, and Nasdaq compliance status directly from Shuttle's most recent SEC filings and a live quote before drawing any conclusions.

Headline figures (approximate, 2026-06-27): RXRX shows revenue (q1 2026) ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates), net loss (q1 2026) ~$117.5 million (narrowed from the prior year on cost cuts), cash and investments ~$665 million (as of March 31, 2026), guided 2026 operating cash burn less than ~$390 million; stated runway into early 2028 without new financing; SHPH shows revenue trend No meaningful product revenue historically; the new Molecule.ai platform is early and any commercial revenue is unproven, profitability Deeply unprofitable; the latest annual report described a net loss of roughly $11.7 million with ongoing cash burn, balance sheet Weak; management flagged a working-capital deficit and substantial doubt about the company's ability to continue as a going concern, offset only by repeated capital raises, valuation A speculative micro-cap valued on narrative and potential rather than earnings or revenue; traditional multiples do not meaningfully apply.

RXRX and SHPH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RXRX and SHPH exposure against your real portfolio. It is not an investment adviser.